Innovative Breakthrough in Cancer Treatment: Inside the Tumor
Cancer is a diagnosis that brings fear and uncertainty. Despite major advances in modern medicine, many cancers, especially solid tumors such as gastric, lung, and liver cancers, remain difficult to treat. Researchers at the Korea Advanced Institute of Science and Technology (KAIST) may have identified a new approach that could change how these tumors are targeted.
Unlocking the Immune System Within Tumors
A research team led by Professor Ji-Ho Park at KAIST focused on immune cells already present inside tumors. Macrophages, which are immune cells capable of engulfing and destroying cancer cells, are often suppressed by the tumor environment and rendered ineffective. The KAIST researchers set out to reverse that suppression and reactivate these cells from within.
Their approach centers on delivering therapy directly into the tumor, where macrophages are already present. Once exposed to the treatment, these dormant cells absorb it and transform into CAR-macrophages—immune cells specifically programmed to recognize and attack cancer. This strategy allows the immune response to originate inside the tumor itself.
Why Solid Tumors Are So Difficult to Treat
Solid tumors are notoriously resistant to treatment because of their dense, tightly packed structure, which prevents many immune cells and therapies from penetrating effectively. This physical barrier limits the success of conventional immunotherapies.
Macrophages, however, are uniquely suited to operate in this environment. They can infiltrate tumors, engulf cancer cells directly, and activate surrounding immune responses, making them a promising tool for overcoming these obstacles.
Limitations of Traditional CAR-Macrophage Therapy
Existing CAR-macrophage treatments require immune cells to be extracted from a patient, modified in a laboratory, and then reinfused. This process is time-consuming, costly, and difficult to scale.
The KAIST team pursued a simpler alternative by targeting macrophages already inside the tumor, eliminating the need for cell extraction and external modification.
Reprogramming Immune Cells On-Site
To achieve this, researchers developed lipid nanoparticles that macrophages naturally absorb. These particles carry mRNA that programs the cells to recognize cancer, along with an immune-stimulating compound. When injected directly into the tumor, macrophages absorb the nanoparticles and rapidly convert into active CAR-macrophages on location.
Once activated, these cells initiate cancer-killing activity and stimulate broader immune responses, creating a coordinated attack against the tumor.
Promising Results in Early Studies
In animal studies involving melanoma models, the treatment significantly reduced tumor growth. Researchers also observed signs that the immune response extended beyond the treated tumor, suggesting potential protection throughout the body.
Professor Park described the work as “a new concept of immune cell therapy that generates anticancer immune cells directly inside the patient’s body,” addressing key limitations of current CAR-macrophage approaches.
What This Means Going Forward
Published in ACS Nano, the study represents an important step in cancer immunotherapy. By activating the body’s own immune defenses directly within tumors, this method could lead to more effective and less invasive treatments.
Beyond the science, this work represents hope for patients and families facing difficult diagnoses. Every advance brings the possibility of safer treatments, better outcomes, and renewed optimism.
While further research is needed, this breakthrough highlights how innovation rooted in real-world challenges can reshape the future of cancer care, bringing us closer to therapies that work with the body, not against it
